Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers

DSpace/Manakin Repository

Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers

Show simple item record

dc.contributor.author O’Connor, Kevin C. en_US
dc.contributor.author Roy, Sushmita Mimi en_US
dc.contributor.author Becker, Christopher H. en_US
dc.contributor.author Hafler, David A. en_US
dc.contributor.author Kantor, Aaron B. en_US
dc.date.accessioned 2014-03-11T10:16:50Z
dc.date.issued 2006 en_US
dc.identifier.citation O’Connor, Kevin C., Sushmita Mimi Roy, Christopher H. Becker, David A. Hafler, and Aaron B. Kantor. 2006. “Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers.” Disease Markers 22 (4): 213-225. doi:10.1155/2006/670439. http://dx.doi.org/10.1155/2006/670439. en
dc.identifier.issn 0278-0240 en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879310
dc.description.abstract Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups. Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent putative biomarkers deserving of further evaluation. en
dc.language.iso en_US en
dc.publisher IOS Press en
dc.relation.isversionof doi:10.1155/2006/670439 en
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851054/pdf/ en
dash.license LAA en_US
dc.title Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers en
dc.type Journal Article en_US
dc.description.version Version of Record en
dc.relation.journal Disease Markers en
dash.depositing.author Hafler, David A. en_US
dc.date.available 2014-03-11T10:16:50Z

Files in this item

Files Size Format View
3851054.pdf 164.9Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters